A lower-dose alternative to tamoxifen may offer a safer path to breast cancer prevention, according to new research from Karolinska Institutet. The study published in the Journal of the National Cancer Institute, suggests that endoxifen, the most active metabolite of tamoxifen, can reduce mammographic breast density to a similar extent while causing fewer side effects, a balance that has long been difficult to achieve in preventive treatment.
A long-standing trade-off in prevention
Tamoxifen has long been a cornerstone of breast cancer therapy and prevention. It is widely used to reduce recurrence in patients and is also approved for women at increased risk of developing the disease. Yet despite its proven efficacy, its use in prevention has been limited.
Many patients discontinue treatment because of side effects, particularly symptoms resembling menopause such as hot flushes and night sweats. These challenges have highlighted a persistent problem in preventive medicine: therapies can be effective, but if they are not tolerable, adherence—and therefore real-world benefit—remains low.
A more direct and potentially precise approach
Endoxifen offers a different strategy. As the active form of tamoxifen produced in the body, it acts directly on estrogen receptors without requiring metabolic conversion. This makes its effects more predictable and may reduce variability between patients.
It also raises an important question: if endoxifen is the molecule responsible for tamoxifen’s therapeutic effect, could it be used at lower doses to achieve the same benefit with fewer side effects?
Strong biological effects at low doses
To test this idea, researchers administered low daily doses of endoxifen to healthy premenopausal women and monitored changes in mammographic breast density over six months.
Breast density is an established risk factor for cancer and is increasingly used as a marker of response to preventive therapy. Higher density is associated with increased risk, while reductions during treatment suggest a beneficial biological effect.
The results were notable. Even at very low doses, endoxifen significantly reduced breast density. A daily dose of one milligram led to a reduction of around 19 percent, while two milligrams achieved a reduction of approximately 26 percent. These effects are comparable to those typically seen with standard-dose tamoxifen, despite using a fraction of the dose.
Improved tolerability at lower doses
Equally important was how patients tolerated the treatment. While the higher dose of endoxifen was associated with an increase in menopausal symptoms, the lower dose showed a safety profile similar to placebo.
“Our results suggest that a lower dose may be sufficient to affect breast density, whilst also appearing to be better tolerated,” said Mattias Hammarström, head of operations KARMA project at the Karolinska Institute and co-author of the study
This finding is particularly significant because tolerability is one of the main barriers to preventive therapy. A drug that maintains efficacy while minimizing side effects could substantially improve adherence and expand the use of preventive strategies.
Rethinking dosing in preventive therapy
The study highlights a broader shift toward precision dosing, finding the minimum effective dose rather than relying on traditional high-dose approaches.
In this case, the data suggest that maximal biological effect may be achieved at relatively low levels of drug exposure. Increasing the dose further may not provide additional benefit but can increase the likelihood of adverse effects.
This principle has important implications not only for breast cancer prevention but also for other areas of medicine, where balancing efficacy and tolerability is critical.
Implications for clinical practice
If confirmed in larger studies, low-dose endoxifen could become an attractive option for women at increased risk of breast cancer who are currently reluctant to use tamoxifen.
By offering a similar reduction in breast density with fewer side effects, it may lower the threshold for initiating preventive treatment and improve long-term adherence.
However, it is important to note that reductions in breast density do not directly prove a reduction in cancer risk. Longer-term studies will be needed to determine whether these biological changes translate into meaningful clinical outcomes.
Looking ahead
The findings provide a strong proof of concept that targeting the active metabolite directly, and at lower doses, may offer a more refined approach to prevention.
Future research will focus on confirming these results in larger populations and evaluating long-term effects on cancer incidence. There is also growing interest in integrating such approaches into broader prevention strategies, potentially alongside lifestyle interventions and risk-based screening.
For now, the study offers a promising step toward making preventive therapy both effective and tolerable. By reducing side effects without compromising efficacy, low-dose endoxifen could help overcome one of the key barriers in breast cancer prevention, and bring precision medicine principles into preventive care.
The post Breast Cancer Prevention Drug Endoxifen Shows Promise at Low Doses appeared first on Inside Precision Medicine.